
mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Trial
The story in brief
An experimental mRNA vaccine reduced melanoma recurrence risk by 42% when combined with Pembrolizumab, with 82.2% of patients remaining recurrence-free after 24.6 months. The therapy, personalized to each patient’s tumor, is under investigation for approval and remains in trials to confirm its efficacy.